|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
2008-8-13
|
|
pubmed:abstractText |
Patients with macroscopic stage III melanoma represent a heterogeneous cohort with average 5-year overall survival rates of <30%. With current algorithms, it is not possible to predict which patients will achieve longer-term survival. We hypothesized that molecular profiling could be used to identify prognostic groups within patients with stage III melanoma while also providing a greater understanding of the biological programs underpinning these differences.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5173-80
|
|
pubmed:meshHeading |
pubmed-meshheading:18698035-Adult,
pubmed-meshheading:18698035-Aged,
pubmed-meshheading:18698035-Aged, 80 and over,
pubmed-meshheading:18698035-Algorithms,
pubmed-meshheading:18698035-Disease Progression,
pubmed-meshheading:18698035-Disease-Free Survival,
pubmed-meshheading:18698035-Female,
pubmed-meshheading:18698035-Gene Expression,
pubmed-meshheading:18698035-Gene Expression Profiling,
pubmed-meshheading:18698035-Humans,
pubmed-meshheading:18698035-Male,
pubmed-meshheading:18698035-Melanoma,
pubmed-meshheading:18698035-Middle Aged,
pubmed-meshheading:18698035-Oligonucleotide Array Sequence Analysis,
pubmed-meshheading:18698035-Prognosis,
pubmed-meshheading:18698035-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:18698035-Skin Neoplasms
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Predicting clinical outcome through molecular profiling in stage III melanoma.
|
|
pubmed:affiliation |
Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Australia.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
